EMEA in 2001-2002: • Activities will increase as the number of applications increases • Post-marketing activities will increase as a consequence of the increased number of centrally authorised medicinal products • New activities relating to orphan drugs, Pan-European Regulatory Forum II, ICH and VICH, clinical trials, medical devices containing blood derivatives • Increased need for communication, transparency and information technology development • Re-organisation of the human medicines’ units and work of the Committee for Proprietary Medicinal Products (CPMP) in